Rafael Holdings (NYSE:RFL), the parent of Rafael Pharmaceuticals, has announced that Ashok Marin has agreed to join the company’s management team. Ashok will support the company’s quest to become a “fully integrated cancer metabolism therapeutics company.”
Marin has also worked for Gilead, Immunomedics, Mallinckrodt Pharmaceuticals, BD and Sanofi.
Rafael Holdings appointed a new chief financial officer, Patrick Fabbio, earlier this month.
“We are continuing to build a highly experienced management team with the skillset necessary to advance the ongoing and planned clinical trial programs across multiple indications and the early-stage pipeline,” said Ameet Mallik, Rafael Holdings CEO, in a statement.
Rafael Holdings plans to merge with Rafael Pharmaceuticals to form a publicly traded, late-stage cancer therapeutics firm.
The company is prepping for the top-line data re…